Switch theme
Sign up to access all valuation multiples
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
2018
181
LTM Revenue $140M
LTM EBITDA -$197M
$177M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Day One Biopharmaceutical has a last 12-month revenue (LTM) of $140M and a last 12-month EBITDA of -$197M.
In the most recent fiscal year, Day One Biopharmaceutical achieved revenue of $131M and an EBITDA of -$215M.
Day One Biopharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Day One Biopharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $140M | XXX | $131M | XXX | XXX | XXX |
| Gross Profit | $131M | XXX | $126M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | -$197M | XXX | -$215M | XXX | XXX | XXX |
| EBITDA Margin | -141% | XXX | -164% | XXX | XXX | XXX |
| EBIT | -$194M | XXX | -$217M | XXX | XXX | XXX |
| EBIT Margin | -139% | XXX | -166% | XXX | XXX | XXX |
| Net Profit | -$113M | XXX | -$95.5M | XXX | XXX | XXX |
| Net Margin | -81% | XXX | -73% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Day One Biopharmaceutical's stock price is $6.
Day One Biopharmaceutical has current market cap of $647M, and EV of $177M.
See Day One Biopharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $177M | $647M | XXX | XXX | XXX | XXX | $-1.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Day One Biopharmaceutical has market cap of $647M and EV of $177M.
Day One Biopharmaceutical's trades at 1.4x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Day One Biopharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Day One Biopharmaceutical has a P/E ratio of -5.7x.
See valuation multiples for Day One Biopharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $647M | XXX | $647M | XXX | XXX | XXX |
| EV (current) | $177M | XXX | $177M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -6.8x | XXX | XXX | XXX |
| EV/FCF | -1.9x | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDay One Biopharmaceutical's last 12 month revenue growth is 34%
Day One Biopharmaceutical's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.9M for the same period.
Day One Biopharmaceutical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Day One Biopharmaceutical's rule of X is -56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Day One Biopharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | -141% | XXX | -164% | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -130% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 174% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 262% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Day One Biopharmaceutical acquired XXX companies to date.
Last acquisition by Day One Biopharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Day One Biopharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Day One Biopharmaceutical founded? | Day One Biopharmaceutical was founded in 2018. |
| Where is Day One Biopharmaceutical headquartered? | Day One Biopharmaceutical is headquartered in United States of America. |
| How many employees does Day One Biopharmaceutical have? | As of today, Day One Biopharmaceutical has 181 employees. |
| Who is the CEO of Day One Biopharmaceutical? | Day One Biopharmaceutical's CEO is Dr. Jeremy Bender, M.B.A.,PhD. |
| Is Day One Biopharmaceutical publicy listed? | Yes, Day One Biopharmaceutical is a public company listed on NAS. |
| What is the stock symbol of Day One Biopharmaceutical? | Day One Biopharmaceutical trades under DAWN ticker. |
| When did Day One Biopharmaceutical go public? | Day One Biopharmaceutical went public in 2021. |
| Who are competitors of Day One Biopharmaceutical? | Similar companies to Day One Biopharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Day One Biopharmaceutical? | Day One Biopharmaceutical's current market cap is $647M |
| What is the current revenue of Day One Biopharmaceutical? | Day One Biopharmaceutical's last 12 months revenue is $140M. |
| What is the current revenue growth of Day One Biopharmaceutical? | Day One Biopharmaceutical revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Day One Biopharmaceutical? | Current revenue multiple of Day One Biopharmaceutical is 1.3x. |
| Is Day One Biopharmaceutical profitable? | Yes, Day One Biopharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Day One Biopharmaceutical? | Day One Biopharmaceutical's last 12 months EBITDA is -$197M. |
| What is Day One Biopharmaceutical's EBITDA margin? | Day One Biopharmaceutical's last 12 months EBITDA margin is -141%. |
| What is the current EV/EBITDA multiple of Day One Biopharmaceutical? | Current EBITDA multiple of Day One Biopharmaceutical is -0.9x. |
| What is the current FCF of Day One Biopharmaceutical? | Day One Biopharmaceutical's last 12 months FCF is -$92.5M. |
| What is Day One Biopharmaceutical's FCF margin? | Day One Biopharmaceutical's last 12 months FCF margin is -66%. |
| What is the current EV/FCF multiple of Day One Biopharmaceutical? | Current FCF multiple of Day One Biopharmaceutical is -1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
